CervoMed (CRVO) Enterprise Value (2010 - 2026)
CervoMed (CRVO) posted Enterprise Value of -$12.9 million for Q1 2026, up 38.06% sequentially from -$20.9 million in Q4 2025, and up 63.33% YoY from -$7.9 million in Q1 2025.
CervoMed (CRVO) Enterprise Value (2010 - 2026) Analysis & Trends
CervoMed has reported Enterprise Value for 17 years, with the latest figure at -$12.9 million in Q1 2026.
- Quarterly Enterprise Value rose 63.33% year-over-year to -$12.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.9 million (up 63.33% YoY) and the FY2025 annual result came in at -$20.9 million, up 46.39% from the prior year.
- Enterprise Value improved to -$12.9 million in Q1 2026 per CRVO's latest filing, from -$20.9 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$6.4 million in Q1 2024 and troughed at -$46.5 million in Q3 2024.
- A 5-year average of -$24.8 million and a median of -$25.9 million in 2022 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value jumped 63.89% in 2024, then sank 453.36% in 2025.
- Over 5 years, Enterprise Value stood at -$16.5 million in 2022, then soared by 52.78% to -$7.8 million in 2023, then plunged by 399.46% to -$38.9 million in 2024, then soared by 46.39% to -$20.9 million in 2025, then jumped by 38.06% to -$12.9 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$12.9 million, -$20.9 million, and -$27.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | CervoMed | 26.12 Mn | 26.12 Mn | - | -24.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.94 Mn |
| Mar 31, 2026 | -12.92 Mn |
| Dec 31, 2025 | -20.86 Mn |
| Sep 30, 2025 | -27.29 Mn |
| Jun 30, 2025 | -33.53 Mn |
| Mar 31, 2025 | -35.24 Mn |
| Dec 31, 2024 | -38.92 Mn |
| Sep 30, 2024 | -46.47 Mn |
| Jun 30, 2024 | -45.09 Mn |
| Mar 31, 2024 | -6.37 Mn |
| Dec 31, 2023 | -7.79 Mn |
| Sep 30, 2023 | -10.42 Mn |
| Jun 30, 2023 | -15.00 Mn |
| Mar 31, 2023 | -17.64 Mn |
| Dec 31, 2022 | -16.50 Mn |
| Sep 30, 2022 | -25.86 Mn |
| Jun 30, 2022 | -28.54 Mn |
| Mar 31, 2022 | -32.55 Mn |
| Dec 31, 2021 | -37.31 Mn |
| Sep 30, 2021 | -40.34 Mn |